1 / 45

The Fibroblast in Tumorigenesis

The Fibroblast in Tumorigenesis. Stroma. Structural Supportive Dynamic regulatory role Epithelial-Stromal/Mesenchymal interactions Developmentally: esp higher Postdevelopmentally Pathologically. Stroma and Cancer. Initial focus on cell-autonomous aspects of cancer

cleary
Download Presentation

The Fibroblast in Tumorigenesis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Fibroblast in Tumorigenesis

  2. Stroma • Structural • Supportive • Dynamic regulatory role • Epithelial-Stromal/Mesenchymal interactions • Developmentally: esp higher • Postdevelopmentally • Pathologically

  3. Stroma and Cancer • Initial focus on cell-autonomous aspects of cancer • Increasing awareness of non-cell autonomous mechanisms • Tumors not pure: intimate admixture of cells suggests symbiosis • “Who is invading who?” • From early stages, tumors seam to be able to recruit / subvert adjacent tissues • Also important for metastasis: e.g. sc vs ortho • Additional consideration: is adjacent tissue normal?

  4. Stroma and Cancer contd • In terms of volume, stroma may predominate (breast, colon, stomach, panc) • Stromal response, Desmoplastic response, Desmoplasia…desmos (Gr): a band • Characterized by marked ECM changes: collagens, FN, PGs, GAGs • Infiltration of vessels, inflammatory cells

  5. “Tumors as wounds that do not heal”

  6. Fibroblasts and Myofibroblasts • The major stromal cell type in most cancers • Slender fusiform smooth nucleus • Well developed Golgi • Numerous RER cisternae • Usu smooth cell contour / few short extensions • No plasmalemmal attachments, plaques, dense patches, basal lamina, IC junctions or cell-to-stroma attachment sites

  7. Fibroblast Ultrastructure

  8. Myofibroblast • Irregular cellular outlines, numerous long extensions • Connected by adherens and gap junctions • Partly enveloped by basal lamina with attachment plaques, dense patches, pinocytotic vesicles • Cell stromal attachment sites • Cytoplasmic stress fibers

  9. Myofibroblast ultrastructure

  10. Myofibroblast phenotype • FBMFB: Activation of a partial smooth muscle differentiation program: express vimentin, alpha sm actin, sm myosin heavy chain, desmin, calponin, alpha1 integrin • Altered function: • Increased proliferation rate • Altered ECM protein expression: increased collagens III, V, decreased Laminin, increased MMPs, TIMPs, GFs

  11. Induction of the Phenotype • Stromal response to diverse injurious stimuli: injury/wounding, radiation, cancer, pulmonary hypertension/fibrosis, bleomycin lung toxicity • Desmoplasia mainly due to myofibroblasts: large amounts of collagen and contractile ability • Some observations in Breast cancer: Higher proportion in invasive vs in situ In invasive ca: seen mainly at invasive front, the younger areas (vs central zone) In in situ: seen in immediate periphery Mechanism…

  12. In Vitro Phenotype of “Carcinoma Associated Fibroblasts” • Enhanced collagen, hyaluronate synthesis • Disorganized growth patterns • Uncontrolled growth, altered proliferation potential, abnormal migratory behaviour • Increased growth factors: IGF I II, PDGF, TGF beta, HGF, KGF • Essentially equivalent to myofibroblasts

  13. Expression of “fetal phenotypes” in Cancer patients and Hereditary Cancer patients (Schor 1986, 1988) • Migratory behavior on 3D collagen gels • “Cell density migration index”(migration of normal vs transformed fibroblasts differentially affected by plating density with an inverse correlation in normals) • Ranges of values for adult, fetal, transformed cells • Fetal phenotype in 17/34 Patients with no previous family history breast cancer (11 benign disease, 23 Cancer) 15/16 patients with +family history of breast cancer (9 benign, 7 cancer) 2/2 1st degree (healthy) relatives of breast cancer patients

  14. Antecol (1986) • Skin fibroblasts from patients with hereditary cancer syndromes (including HNPCC) show Disorganized actin Disorganized growth patterns Decreased requirements for serum in vitro • Thus far: tumors associated with fibroblasts with altered morphology and behaviour • Epiphenomenon vs facilitative (even causitive)? • Do CAFs promote tumor growth?

  15. Can CAFs direct progression of initiated human prostate epithelium? (Olumi 1999) • Hypothesis: CAFs may affect tumor progression in non-tumorigenic cells • Experiments equivalent to study of genetic determinants of tumorigenesis (initiation, promotion etc) • Grew CAFs with initiated (TAg) or normal PECs • Looked at change in tumorigenesis and indices (morphology, RIP, proliferation) • In vivo strategy: mixed ECs and CAFs and set in collagen gel, then under renal capsule of athymic mice

  16. CAFs cause dramatic tumor progression when grafted as tissue recombinants with initiated ECs in vivo

  17. Experimental Manipulation of Stroma to become “Oncogenic” (in absence of tumor) • Carcinogen-treated stroma heterotypically grafted with untreated ECs (skin, bladder)  increased tumorigenicity • Barcellos-Hoff (2000) looked at the effects of irradiated vs non-irradiated (epithelium-free) mammary stroma on promotion of tumorigenesis • COMMA-D cells (p53 mutations, yet non-tumorigenic and retain developmental potential) • Cell transplanted into epithelium-free mammary fat pads (irradiated and non-irradiated)

  18. Tumor incidence at 6 weeks 81%+/-12SE (Irrad) vs 19%+/-2SE (Sham) • Tumor Size 243mm+/-61.3 (Irrad) vs 30.8mm+/-8.7 (Sham) • Speed of appearance • 100% by 6wks (Irrad) vs 39% by 10wks (Sham) • Local vs global effects assessed by hemibody radiation: no tumors on non-irradiated side

  19. Mouse models of stromal contribution to tumor progression • HPV 16-Ker 14 Mice: develop multistage squamous neoplasia: EHADSCCMet • MMP 9 upregulated early in neoplasia • Crossed to MMP 9 KO mice: delay in dysplasia formation and fewer carcinomas • Restriction in keratinocyte hyperproliferation • Marrow ablation and transplantion of MMP 9+ hematopoietic cells restores the hyperproliferative phenotype and rate of carcinoma formation

  20. Mouse models of stroma aiding progression (contd) • mmtv-PyMT x (Csf-1op /Csf-1op) • Recessive null mutation in Csf-1 • Early stages of tumorigenesis are preserved • Attenuation of late stages of invasion/metastasis • Difference appears to be in macrophage recruitment rather than a direct proliferative effect on tumor • Targeting Csf-1 to mammary epithelium restores MPh recruitment and metastatic potential • (But ?autocrine effects)

  21. Clear stromal role in aiding progression • Role in Initiation? Hints from “fetal fibroblasts, stromal genetic changes.. Sternlicht 1999, Thomasset 1998 • Experimental evidence for initiating effects: • Autoactivated MMP-3/Str-1 in mammary epithelium (WAP promoter) – see the following • Reactive stroma • Mulistage neoplastic progression • TIMP-1 double transgenic: decrease tumorigenesis • Tumors show non-random chromosomal changes

  22. Reactive Stroma in Stl-1 Transgenic mice

  23. Aetiology of “Oncogenic stroma” 1. Cross talk from tumor: co-culture experiments have shown tumor induced FBMFB (gradated pattern of myogenic differentiation) (Ronnov-Jessen, Bissell) 2. Carcinogens (as before) 3.Wound healing: Increased tumor risk at areas of scarring, also areas of chronic inflammation. TGF-beta, DNA damage 4. Stromal Senescence 5.Viral

  24. 5. Viral effect on stroma • Interleukin-6 promotes growth in Multiple Myeloma • HHV8 (Kaposi’s associated) encodes Interleukin-6 • Rettig examined MM samples for viral sequences • Found them…

  25. 6. Stromal Genetic changes • Concurrent, Independent LOH in stroma as well as epithelium in DCIS • Mutations in stromal cells: Juvenile Polyposis TSG locus at 10q22

  26. 3. Haploinsufficiency of stromal cells • Neurofibromas: benign tumors of peripheral nerve sheath, but heterogenous (Schwann cells, axons, perineurial cells, fibroblasts), thought reactive hyperplasias in past • NF1: familial cancer syndrome: germline mutation in neurofibromin, a member of the RasGAP family • Nf1-/- die before birth. Nf1+/- don’t get neurofibromas • Conditional Nf1 model: floxed Nf1 allele deleted by Cre transgene under control of Schwann cell-specific promoter Krox-20 • Nf1flox/-;Krox20-cre develop neurofibromas: SC origin

  27. To assess the effects of heterozygosity for Nf1 in the neighboring cells, compared Nf1flox/-;Krox20-cre (heterozygous stroma) Nf1flox/flox;Krox20-cre (wild type stroma) • ?Heterozygosity in which cell type

  28. Epithelial-Fibroblast Heterotypic signaling 1. TGF-beta • Protean effects, contribution is not straight forward - supressive at early stages, facilitative in late stages; elevated in many cancers, yet tumors often have mutated pathway (TGFbRI,II, SMAD2 4, Rb)  ?suggests a paracrine effect; can have tumor autonomous effects (EMT, SC cell lines more “fibroblastoid” in vivo) • Important in desmoplastic response • Preferentially exp at advancing edges and in LN suggests involvement in tumor – stromal interaction • In vitro: TGFb  FB  MFB • Role in bone metastasis..

  29. 2. Epithelial PDGF expression • Potent mitogen, chemoattractant for mesenchymal cells • PDGF autocrine signaling loops can cause tumorigenesis (FB, Glia), but not usually in carcinomas (no R) • Suggests contribution is via paracrine mechanisms • Essential for desmoplastic response in a Human BrCa xenograft model: abrogated by dom neg PDGF-A • Mechanism of promoting desmoplasia not clear: mitogenic to FB but does not induce FB  MFB: maybe works via MPh recruitment 3.VEGF / Angiogenesis • VEGFs may play an indirect role in early stages of desmoplasia via increased vascular permeability: fibrin clots  infiltration of inflammatory vessels and blood vessels (correlation: VEGF and desmoplasia in some tumors)

  30. 3. Fibroblast produced ECM • ECM tends to promote tumorigenesis • Coinjection of Matrigel with tumor cells enhances efficiency, decreases latency, even when stripped of GF • Coinjection of killed fibroblasts with tumor cells: enhanced efficiency of tumor establishment, but did not increase the rate of growth (vs live FB) – early effect • 4. Fibroblast produced Growth Factors • May have paracrine effect on tumors, tumors may be dependent on these in early stages, then become independent (?difficulty in culturing primary human breast cancers) • IGF I, II, HGF, EGF family (Strong stromal expression of AR, HRG is the prognostic factor) • Another mechanism for growth factor regulation: Regulation of accessibility of GFs in the ECM (EGF family, TGFb, PDGF, b-FGF etc) • Fibroblasts may be key gatekeepers e.g. via protease production

  31. 1. Stand in for oncogenic signaling (need only be temporary) • 2. Increase in genomic instability • 3. Supports / regulates angiogenesis • 4. Selective pressure • 4. Protect from host response • etc

More Related